This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Curis Reports Second Quarter 2013 Financial Results

LEXINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today reported its financial results for the second quarter ended June 30, 2013.

"The second quarter and recent weeks have been highlighted by significant advances within our proprietary programs, including the recent initiation of the first of three planned clinical trials with our IAP antagonist, CUDC-427," said Ali Fattaey, President and Chief Operating Officer of Curis. "We plan to initiate the second trial in HER2 negative breast cancer patients in combination with capecitabine and a third trial in patients with certain aggressive and indolent lymphomas, including MALT lymphomas, which are often associated with genetic aberrations of the molecular targets of CUDC-427."

Dr. Fattaey continued, "We are also encouraged with the progress of our ongoing Phase 1 clinical study of dual targeted PI3K and HDAC inhibitor, CUDC-907. We continue to enroll patients and expect to report interim data from this study later this year."

"In addition to our efforts on Curis' proprietary programs, our collaborator Genentech/Roche continues to successfully advance its global commercialization strategy for Erivedge®, with recent regulatory approvals in the European Union and Australia, among others," said Dan Passeri, Chief Executive Officer of Curis. "We are also highly encouraged with Erivedge's sales growth, with Roche reporting a net sales increase of approximately 22% in the second quarter versus the previous quarter. We expect continued growth in the U.S. market and anticipate Roche's commercial launch in additional markets in the coming months."

Second Quarter 2013 Financial Results

Curis reported a net loss of $1.3 million, or ($0.02) per share on both a basic and fully diluted basis for the second quarter of 2013, as compared to a net loss of $2.9 million or ($0.04) per share on both a basic and fully diluted basis for the same period in 2012. Curis reported a net loss of $6.3 million, or ($0.08) per share on both a basic and fully diluted basis for the six months ended June 30, 2013, as compared to a net loss of $661,000 or ($0.01) per share on both a basic and fully diluted basis for the same period in 2012.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs